Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II Study of Renadirsen in DMD
NCT02667483Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Oct 2015
- Primary completion
- Oct 2020
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
A Phase 2 trial of renadirsen in Duchenne muscular dystrophy (DMD), sponsored by Daiichi Sankyo Co., Ltd.. Started Oct 2015; status: completed.
02
Drugs
renadirsen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT02667483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02667483.